Viking Therapeutics jumps after experimental drug shows durable weight-loss benefit
22/09/2026 12:30
BUZZ-Viking Therapeutics jumps after experimental drug shows durable weight-loss benefit ** Shares of Viking Therapeutics VKTX.O rise 41.2% to $42.32 premarket
** Weight-loss drug developer says patients who switched to every-other-week dosing of experimental drug VK2735 maintained up to 97% of the weight they had lost during an initial 21-week treatment period in a study
** Those moved to monthly dosing retained up to 90% of their prior weight loss over the following 12 weeks
** Up to last close, stock down 14.4% YTD
(Reporting by Puyaan Singh)
Recent news on Viking Therapeutics
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry